Trump Unveils “TrumpRx”: The New Digital Clearinghouse For Discounted Drugs (Video)

In a high-profile unveiling tonight, February 5, 2026, President Donald Trump officially launched TrumpRx.gov from the Eisenhower Executive Office Building. Flanked by CMS Administrator Dr. Mehmet Oz and National Design Studio Director Joe Gebbia, the President characterized the platform as a “digital wrecking ball” aimed at the traditional pharmaceutical supply chain. The site is designed to serve as a central clearinghouse where Americans can bypass insurance middlemen—specifically Pharmacy Benefit Managers (PBMs)—to purchase medications at “Most Favored Nation” (MFN) prices directly from manufacturers.

How TrumpRx Functions

Rather than acting as a government pharmacy, TrumpRx.gov operates as a facilitator portal. The “state-of-the-art” interface, designed by the newly formed National Design Studio, allows users to search for medications and view transparent “cash prices.” If a user chooses to proceed, the site redirects them to the manufacturer’s own direct-to-consumer (DTC) platform to complete the purchase.

“We are cutting out the middleman,” President Trump declared during the demonstration. “No more Canadian detours. No more PBM markups. You get the same price as people in Europe and Japan, right here at home with one click.”

The “Big 16” and Blockbuster Discounts

The launch is the culmination of a year-long pressure campaign involving 16 major pharmaceutical companies—including Pfizer, Eli Lilly, Merck, AstraZeneca, and Novo Nordisk. These firms agreed to participate in exchange for a three-year reprieve from proposed Section 232 pharmaceutical tariffs.

Tonight’s announcement confirmed specific pricing for some of the most sought-after medications in the country:

A Strategic Victory Over PBMs

A major revelation during the announcement was the resolution of a standoff with Express Scripts. Under a new settlement involving the FTC, the administration secured a commitment that payments made through TrumpRx can now count toward a patient’s insurance deductible and out-of-pocket maximums. This addresses a primary criticism of “cash-pay” systems, which previously did not benefit insured patients who had not yet met their annual deductibles.

Economic and Manufacturing Strings

The deals go beyond simple price tags. The participating companies have collectively pledged over $150 billion in domestic manufacturing investments.

• Merck and GSK have agreed to donate several tons of active pharmaceutical ingredients (APIs) to a newly created National Strategic Reserve for antibiotics and rescue inhalers.
• Bristol Myers Squibb will provide its signature blood thinner, Eliquis, to Medicaid programs at MFN prices and free of charge for specific high-need demographics.

Industry and Political Pushback

Critics, including Senate Democratic Whip Dick Durbin and Senator Elizabeth Warren, have raised concerns about the platform’s legality and potential conflicts of interest. In a letter sent earlier this week, they questioned the role of BlinkRx, an online dispensing company whose board included Donald Trump Jr. as of 2025.

Policy experts also remain divided. While the $149 price point for GLP-1 drugs (like Wegovy) is a massive reduction from the $1,000+ list prices, they note that for the 85% of Americans with comprehensive insurance, traditional pharmacy co-pays may still be lower once their insurance coverage kicks in.

Conclusion

TrumpRx represents a fundamental shift in federal healthcare policy—moving from government-funded subsidies toward a market-based, “name and shame” negotiation model. By leveraging the threat of tariffs against the promise of a direct-to-consumer pipeline, the administration has created a first-of-its-kind government marketplace that could permanently alter how Americans access and pay for life-saving medicine.

Sources and Links

• Washington Post: Trump to launch TrumpRx.gov, branding his push to lower prescription prices
• AP News: Trump administration to launch TrumpRx website for discounted drugs
• Fierce Pharma: TrumpRx, US government’s cash-pay drug purchasing portal, primed for launch
• The White House: FACT SHEET: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing